Epidemiologic Registry PETHEMA LMA 2015

NCT ID: NCT02607059

Last Updated: 2021-03-23

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

500 participants

Study Classification

OBSERVATIONAL

Study Start Date

2015-05-31

Study Completion Date

2021-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Epidemiologic and retrospective multicenter registry of all patients diagnosed with de novo or secondary acute myeloid leukemia (AML) in the PETHEMA Group institutions. This study is a non-interventional research regarding diagnosis and therapeutic approach

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

To perform this registry, every patient diagnosed with AML in the participant institutions, regardless type of AML and treatment administered, must be reported. It will be required to registry the main characteristics of the patients and AML at diagnosis, as cytomorphologic, immunophenotypic, and cytogenetic results, according to the habitual practice of the centers. The treatment which has been administered by every center of the PETHEMA Group, even when it is considered as supportive care, and evolution of the disease will also be reported (relapse o death). PETHEMA Group will input all the reported information in data bases

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

AML

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Registry

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients diagnosed with acute myeloid leukemia
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

PETHEMA Foundation

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Hospital La Fe

Valencia, , Spain

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Spain

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Pau Montesinos, Dr

Role: CONTACT

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Pau Montesinos, Dr

Role: primary

References

Explore related publications, articles, or registry entries linked to this study.

Labrador J, Martinez-Cuadron D, Boluda B, Serrano J, Gil C, Perez-Simon JA, Bernal T, Bergua JM, Martinez-Lopez J, Rodriguez-Medina C, Vidriales MB, Garcia-Boyero R, Algarra L, Polo M, Sayas MJ, Tormo M, Alonso-Dominguez JM, Herrera P, Lavilla E, Ramos F, Amigo ML, Vives-Polo S, Rodriguez-Macias G, Mena-Duran A, Perez-Encinas MM, Arce-Fernandez O, Cuello R, Sanchez-Garcia J, Gomez-Casares MT, Chillon MC, Calasanz MJ, Ayala R, Rodriguez-Veiga R, Barragan E, Montesinos P; PETHEMA Group. Evolving patterns and clinical outcome of genetic studies performed at diagnosis in acute myeloid leukemia patients: Real life data from the PETHEMA Registry. Cancer. 2024 Oct 15;130(20):3436-3451. doi: 10.1002/cncr.35431. Epub 2024 Jun 19.

Reference Type DERIVED
PMID: 38896056 (View on PubMed)

Martinez-Cuadron D, Megias-Vericat JE, Serrano J, Martinez-Sanchez P, Rodriguez-Arboli E, Gil C, Aguiar E, Bergua J, Lopez-Lorenzo JL, Bernal T, Espadana A, Colorado M, Rodriguez-Medina C, Lopez-Pavia M, Tormo M, Algarra L, Amigo ML, Sayas MJ, Labrador J, Rodriguez-Gutierrez JI, Benavente C, Costilla-Barriga L, Garcia-Boyero R, Lavilla-Rubira E, Vives S, Herrera P, Garcia-Belmonte D, Herraez MM, Vasconcelos Esteves G, Gomez-Roncero MI, Cabello A, Bautista G, Balerdi A, Mariz J, Boluda B, Sanz MA, Montesinos P. Treatment patterns and outcomes of 2310 patients with secondary acute myeloid leukemia: a PETHEMA registry study. Blood Adv. 2022 Feb 22;6(4):1278-1295. doi: 10.1182/bloodadvances.2021005335.

Reference Type DERIVED
PMID: 34794172 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

LAM 2015

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Acute Myeloid Leukemia Registry
NCT05979675 RECRUITING